Cargando…

Safety of selective IL‐23p19 inhibitors for the treatment of psoriasis

Psoriasis is a chronic disease that requires long‐term treatment. Consequently, understanding the safety and tolerability of any potential treatment over time is critical to effective prescribing. The biologic agents currently available for the treatment of psoriasis target a number of different inf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crowley, J.J., Warren, R.B., Cather, J.C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771721/ https://www.ncbi.nlm.nih.gov/pubmed/31054215 http://dx.doi.org/10.1111/jdv.15653

Ejemplares similares

The role of IL‐23 and the IL‐23/T(H)17 immune axis in the pathogenesis and treatment of psoriasis
por: Girolomoni, G., et al.
Publicado: (2017)

Use of Biologic Agents in Combination with Other Therapies for the Treatment of Psoriasis
por: Cather, Jennifer C., et al.
Publicado: (2014)

Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review
por: Blauvelt, Andrew, et al.
Publicado: (2023)

TARGETING IL-23: INSIGHTS INTO THE PATHOGENESIS AND THE TREATMENT OF PSORIASIS
por: Lima, Hermenio Cavalcante, et al.
Publicado: (2010)

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
por: Haugh, Isabel M, et al.
Publicado: (2018)

Compositional Alteration of Gut Microbiota in Psoriasis Treated with IL-23 and IL-17 Inhibitors
por: Huang, Yu-Huei, et al.
Publicado: (2023)

The role of IL-23 in the immunopathogenesis of psoriasis
por: Meglio, Paola Di, et al.
Publicado: (2010)

Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis
por: Yang, Eric J, et al.
Publicado: (2019)

The role of the interleukin‐23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis
por: Egeberg, A., et al.
Publicado: (2020)

Comment on: Drug Survival of IL‑12/23, IL‑17 and IL‑23 Inhibitors for Psoriasis Treatment: A Retrospective Multi‑Country, Multicentric Cohort Study
por: Borg, Emma, et al.
Publicado: (2021)

Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review
por: Yang, Kevin, et al.
Publicado: (2020)

Targeting IL-23 in psoriasis: current perspectives
por: Fotiadou, Christina, et al.
Publicado: (2018)

A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
por: Campa, Molly, et al.
Publicado: (2015)

The Impact of Treatment with IL-17/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and/or Psoriatic Arthritis: A Systematic Review
por: Tsiogka, Aikaterini, et al.
Publicado: (2023)

Evaluation of interleukin-23 receptor (IL-23R) gene polymorphisms and serum IL-23 levels in patients with psoriasis
por: FİLİZ, Başak, et al.
Publicado: (2019)

Indirect Regulation and Equilibrium of p35 and p40 Subunits of Interleukin (IL)-12/23 by Ustekinumab in Psoriasis Treatment
por: Zhou, Jiong, et al.
Publicado: (2020)

Erratum to: A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
por: Campa, Molly, et al.
Publicado: (2016)

Suppression of IL‐12/IL‐23 p40 subunit in the skin and blood of psoriasis patients by Tofacitinib is dependent on active interferon‐γ signaling in dendritic cells: Implications for the treatment of psoriasis and interferon‐driven diseases
por: Vincken, Nanette L. A., et al.
Publicado: (2022)

A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab
por: Ghazawi, Feras M., et al.
Publicado: (2021)

Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders
por: Gooderham, M.J., et al.
Publicado: (2018)

Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
por: Bai, Fan, et al.
Publicado: (2019)

The role of IL‐23 and the use of IL‐23 inhibitors in psoriatic arthritis
por: Fragoulis, George E., et al.
Publicado: (2022)

An Analysis of IL-10, IL-17A, IL-17RA, IL-23A and IL-23R Expression and Their Correlation with Clinical Course in Patients with Psoriasis
por: Kutwin, Magdalena, et al.
Publicado: (2021)

Serum Levels of TNF-α, IL-12/23p40, and IL-17 in Plaque Psoriasis and Their Correlation with Disease Severity
por: Kyriakou, Aikaterini, et al.
Publicado: (2014)

Safety and efficacy of an interleukin 12/23 inhibitor in a patient with constitutional neutropenia and psoriasis vulgaris()()
por: Starek, Jéssica Vianna, et al.
Publicado: (2021)

A non-clinical comparative study of IL-23 antibodies in psoriasis
por: Zhou, Li, et al.
Publicado: (2021)

Apilimod Inhibits the Production of IL-12 and IL-23 and Reduces Dendritic Cell Infiltration in Psoriasis
por: Wada, Yumiko, et al.
Publicado: (2012)

IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitis
por: Goldstein, Jérémie D, et al.
Publicado: (2020)

Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis
por: Wu, J.J., et al.
Publicado: (2022)

Editorial: fixed‐dose combination calcipotriol/betamethasone dipropionate foam in the treatment of patients with psoriasis
por: Lebwohl, M., et al.
Publicado: (2021)

New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors
por: Gaspari, Anthony A, et al.
Publicado: (2015)

Genomewide Scan Reveals Association of Psoriasis with IL-23 and NF-κB Pathways
por: Nair, Rajan P., et al.
Publicado: (2009)

Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period
por: Chan, Yung, et al.
Publicado: (2021)

Skin expression of IL-23 drives the development of psoriasis and psoriatic arthritis in mice
por: Chen, Lili, et al.
Publicado: (2020)

Suppression of IL-23-mediated psoriasis-like inflammation by regulatory B cells
por: Mizumaki, Kie, et al.
Publicado: (2021)

Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis
por: Koutruba, Nora, et al.
Publicado: (2010)

JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis
por: Hsu, Leeyen, et al.
Publicado: (2014)

Addressing challenges associated with long‐term topical treatment and benefits of proactive management in patients with psoriasis
por: Lebwohl, M., et al.
Publicado: (2021)

Ustekinumab in Psoriasis Immunopathology with Emphasis on the Th17-IL23 Axis: A Primer
por: Quatresooz, Pascale, et al.
Publicado: (2012)

Characteristics of anti-IL-17/23 biologics-induced interstitial pneumonia in patients with psoriasis
por: Miyagawa, Hanae, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5di1s5242kr018pketsnpfjjmj